Walkowiak B, Koziołkiewicz W, Michalec L, Pawłowska Z, Krzesłowska J, Cierniewski C S
Department of Biophysics, Medical Academy, Lódź, Poland.
Pol J Pharmacol. 1996 May-Jun;48(3):303-5.
Verapamil is widely used in the treatment of patients with coronary artery disease. The effect of verapamil on vascular smooth muscle cells is well documented. This effect is mediated by the inhibition of calcium fluxes across plasma membranes. Some data suggest that verapamil may affect platelet functions in thrombosis, but those observations were made for much higher verapamil concentration than could be achieved in vivo. Our current investigations are focused on an influence of low doses of verapamil (0.1-1.0 microM) on platelet response to ADP. We have found that verapamil at concentration of 0.1 microM can inhibit platelet aggregation (by 10%) evoked in PRP by 1.0-1.5 microM ADP. Moreover, the inhibitory effect is potentiated by prolonged time of platelet preincubation with verapamil. On the other hand, we have found a significant reduction in the number of fibrinogen receptors exposed on the platelet surface of patients (n = 21) treated with therapeutic doses (240 mg/day) of verapamil during two weeks of drug administration. The mean number of exposed receptors was reduced from 75,000 to 40,000 per platelet, with significance p < 0.0001. In vitro platelet preincubation with verapamil, even in much higher concentrations, did not affect fibrinogen binding to ADP activated platelets. It suggests, that in vitro exposure of platelets to verapamil for a short time has no effect on the expression of fibrinogen receptors on platelets, but prolonged in vivo interaction of this drug with platelets results in reduction of the fibrinogen receptor exposition. Thus, observed inhibition of platelet aggregation does not relay on a simple reduction of the number of exposed receptors, but intraplatelet signalling has to be affected. In fact, we have observed, in platelets pretreated with low doses of verapamil, significantly reduced release of calcium ions upon activation by ADP, whereas the calcium influx under such conditions does not seem to be affected.
维拉帕米广泛用于治疗冠状动脉疾病患者。维拉帕米对血管平滑肌细胞的作用已有充分记录。这种作用是通过抑制跨质膜的钙通量介导的。一些数据表明,维拉帕米可能会影响血栓形成中的血小板功能,但这些观察是在比体内所能达到的浓度高得多的维拉帕米浓度下进行的。我们目前的研究集中在低剂量维拉帕米(0.1 - 1.0微摩尔)对血小板对ADP反应的影响。我们发现,浓度为0.1微摩尔的维拉帕米可抑制PRP中由1.0 - 1.5微摩尔ADP诱发的血小板聚集(达10%)。此外,维拉帕米与血小板预孵育时间延长可增强抑制作用。另一方面,我们发现,在接受为期两周治疗剂量(240毫克/天)维拉帕米治疗的患者(n = 21)中,血小板表面暴露的纤维蛋白原受体数量显著减少。每个血小板暴露受体的平均数量从75,000减少到40,000,p值< 0.0001,具有统计学意义。即使在更高浓度下,体外将血小板与维拉帕米预孵育也不会影响纤维蛋白原与ADP激活的血小板的结合。这表明,体外将血小板短时间暴露于维拉帕米对血小板上纤维蛋白原受体的表达没有影响,但该药物在体内与血小板的长时间相互作用会导致纤维蛋白原受体暴露减少。因此,观察到的血小板聚集抑制并非仅仅依赖于暴露受体数量的简单减少,而是血小板内信号传导必定受到了影响。事实上我们观察到,在经低剂量维拉帕米预处理的血小板中,ADP激活后钙离子的释放显著减少,而在这种情况下的钙内流似乎未受影响。